Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,911 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07052669RecruitingPhase 3
Shorter Chemo-Radiation Plus Immunotherapy for Stage III Lung Cancer
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06367218Recruiting
Opioid-free anesthesia with spontaneous breathing for VATS lung nodule surgery
This trial tests a way to do VATS lung nodule surgery without using strong painkillers (opioids) and while you keep breathing on your own. It may help you recover faster with fewer side effects.
Wuhan, HubeiAges 18–70 - NCT06361589Recruiting
Lorlatinib for advanced ALK-positive lung cancer
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
Chengdu, SichuanAges 18 years+ - NCT06321848Recruiting
Ultrasound to guide weaning from a breathing machine
This trial uses ultrasound pictures of the heart, lungs, and diaphragm (a muscle that helps you breathe) to help doctors decide when to take a patient off a breathing machine after surgery. It may help make the weaning process safer and more personalized.
HanoiAges 18 years+ - NCT06276530Recruiting
Lung surgery: large incision vs. robotic approach and breathing
This study compares how different types of lung surgery (a large incision vs. robotic-assisted small cuts) affect your posture and breathing. It aims to help doctors choose the best approach for recovery.
ParisAges 18 years+ - NCT06290869RecruitingPhase 3
Tobacco education and lung scan study
This study tests whether a special health education program, along with a free lung scan, can help long-term smokers quit. You may be able to join if you are a current smoker between 50 and 80 years old and have never had lung cancer.
Washington D.C., District of ColumbiaAges 50–80 - NCT04008368RecruitingPhase 1/Phase 2
Second stem cell transplant for sickle cell with declining donor cells
This Phase 1/2 study tests whether repeating a stem cell transplant can help people with sickle cell disease (SCD) whose donor cells are no longer holding strong. It may help restore healthier blood cell production and reduce symptoms such as pain crises and severe anemia.
Bethesda, MarylandAges 2–80 - NCT06479759RecruitingPhase 2
LM-108 with sintilimab for advanced lung cancer
This trial tests a new antibody combination for non-small cell lung cancer that has spread or come back. It may help people whose cancer stopped responding to immunotherapy or who haven't had treatment yet.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06203249Recruiting
Exploring lung health and immune system in a rare muscle disease
This trial looks at how the immune system and tiny organisms in the lungs may affect a rare condition called anti-MDA5 positive dermatomyositis, which can cause serious lung disease. It may help doctors understand why some patients get worse quickly and how to better treat them.
Beijing, Beijing MunicipalityAges 18–100 - NCT06178510Recruiting
Breathing support after heart surgery
This trial tests a new way to help patients breathe after heart surgery. It compares standard breathing support with a new device that might help you recover faster in the ICU.
Vienna, State of ViennaAges 18–120 - NCT07725510Recruiting
Comparing two special microscope techniques during lung biopsy
This study compares two advanced imaging methods (CLE and ROSE) used during a bronchoscopy to check lung samples right away. The goal is to see which technique better helps doctors get a clear diagnosis from a small lung nodule.
Guangzhou, GuangdongAges 18 years+ - NCT07003672Recruiting
Weaning from ventilator: a lung measurement study
This study looks at people who have a tracheostomy and have been on a breathing machine for at least two weeks. Researchers want to see if certain lung measurements can help predict how easy or hard it will be to come off the ventilator.
TaipeiAges 20 years+ - NCT07737093Recruiting
Comparing two breathing devices after lung surgery
This trial compares two handheld devices (Acapella and Flutter) to see which works better at helping you clear mucus and improve your breathing after lung lobe removal surgery.
Lahore, Punjab ProvinceAges 35–54 - NCT07672106Recruiting
Predicting breathing tube need after major surgery recovery
This study watches patients after major surgery to see which factors may increase the chance of needing a breathing tube again. It helps doctors better predict and prevent breathing problems in the intensive care unit.
Istanbul, ŞişliAges 18 years+ - NCT06112951Recruiting
ECP treatment for early signs of lung transplant rejection
This trial tests whether a therapy called extracorporeal photopheresis (ECP) can stop early, silent rejection in lung transplant patients. It is for people who have developed donor-specific antibodies but still have normal lung function.
ViennaAges 18 years+ - NCT06115395Recruiting
Non-invasive ventilation for bronchoscopy
This trial uses a breathing mask (non-invasive ventilation) to help people who need a bronchoscopy. It aims to make the procedure safer and more comfortable for those with breathing problems.
Al MansurahAges 18–70 - NCT06638554Recruiting
Using video visits to help people get screened for lung cancer
This trial tests whether telehealth (video visits) can help more people get screened for lung cancer. It may be a good fit if you are between 50 and 80, have a history of smoking, and have not had a lung cancer screening in the last two years.
Philadelphia, PennsylvaniaAges 50–80 - NCT06371482RecruitingPhase 2
Durvalumab plus chemoradiation for limited-stage small cell lung cancer
This trial tests adding the immunotherapy drug durvalumab to standard chemotherapy and radiation for limited-stage small cell lung cancer. The goal is to see if this combination helps control the cancer better than standard treatment alone.
Shijiazhuang, HebeiAges 18–75 - NCT06106802RecruitingPhase 2
Testing lazertinib and tepotinib for EGFR lung cancer that progressed on lazertinib
This trial tests a combination of two targeted drugs, lazertinib and tepotinib, for people with advanced EGFR-mutant non-small cell lung cancer whose tumors show MET overactivity (high MET levels or MET gene copies) and have grown despite prior treatment with lazertinib. It aims to see if adding tepotinib can overcome that resistance.
Seoul, Gangnam-guAges 19 years+ - NCT06107374RecruitingPhase 2
New imaging for immunotherapy in advanced lung cancer
This trial tests a special imaging scan called [18F]-FARAG to see how well it shows the activity of immunotherapy in advanced NSCLC. The goal is to help doctors understand if the treatment is working earlier than standard scans.
Iowa City, IowaAges 18 years+ - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT05429463RecruitingPhase 3
Surgery-ready lung cancer treatment with immunotherapy plus chemo
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
Hangzhou, ZhejiangAges 18–75 - NCT06491862Recruiting
Lung cancer care after chemo in Brazil
This study looks at how doctors in Brazil treat non-squamous non-small cell lung cancer after platinum chemotherapy stops working. It aims to understand real-world outcomes and help improve future care.
Belo Horizonte, Minas GeraisAges 18 years+ - NCT06487078Recruiting
Study of Lorlatinib for untreated ALK-positive lung cancer
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
Paris, ParisAges 18 years+
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,911 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.